What Triggers a Paragraph IV Filing: The Definitive Analyst’s Guide to Drug Patent Challenge Predictors
The 55% figure should stop every pharma IP team in its tracks. That is the share of new small-molecule drugs […]
Generic Drug Partnerships: The Definitive IP and Deal Structure Playbook for ANDA Filers
Generic drug development has never been a solo endeavor, but the industry has spent the last decade pretending otherwise. Companies
Generic Drug Partnerships: The Definitive IP and Deal Structure Playbook for ANDA Filers Read Post »
Generic Drug Development Timelines: The Definitive Playbook for Faster ANDA Approval
The average generic drug program takes 3 to 4 years from target identification to FDA approval. For most companies, that
Generic Drug Development Timelines: The Definitive Playbook for Faster ANDA Approval Read Post »
Using Drug Patents to Block Competitors: The Tactics and Consequences
Strategic Patent Barriers and Market Exclusivity in the Pharmaceutical Industry Pharmaceutical companies use patent portfolios to prevent generic and biosimilar
Using Drug Patents to Block Competitors: The Tactics and Consequences Read Post »
Fix Your Generic Drug Supply Chain Before a Shortage Does It for You
How AI, blockchain, multi-sourcing, and smarter policy can cut costs, eliminate fragility, and keep patients supplied Generic drugs fill 89%
Fix Your Generic Drug Supply Chain Before a Shortage Does It for You Read Post »
The Patent Cliff Playbook: Pharmaceutical IP Valuation, Generic Entry Timing, and Biosimilar Strategy
A technical deep dive for pharma IP teams, R&D leads, and institutional investors Master Key Takeaways A drug’s market monopoly
Latin America Specialty Generics: The Complete IP, Regulatory & Market Entry Playbook
For pharma IP teams, portfolio managers, R&D leads, and institutional investors who need more than headline growth figures. Executive Summary
Latin America Specialty Generics: The Complete IP, Regulatory & Market Entry Playbook Read Post »
Drug Patent Marketing Strategy: The Complete Playbook for Maximizing Exclusivity, IP Value, and Peak Sales
A patent does not generate revenue. A masterfully executed commercial strategy does. This guide breaks down exactly how pharmaceutical companies,
The Real Cost of Generic Drug Production: A Full-Stack Analysis
1. The Structural Economics of Generic Affordability 1.1 The Arithmetic Behind the 80-85% Discount Generic drugs fill roughly 90% of
The Real Cost of Generic Drug Production: A Full-Stack Analysis Read Post »
